TiGenix Report issue

For profit Phase 2 Phase 3
Founded: Leuven Belgium (2000)
Status: Acquired by Takeda (2018)

Organization Overview

First Clinical Trial
2002
NCT00414700
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

TiGenix n.v. | TiGenix S.A.U.

Active Ingredients

Drugs in Phase 3 Trials (4)

Key: TiGenix (2) Acquired (2)

allogeneic adipose derived mesenchymal stem cell (5 trials)

autologous adipose-derived mesenchymal stem cells (2 trials)

chondrocelect (1 trial)

human fibrin (Tisseel) (1 trial)

Drugs in Phase 2 Trials (2)

Key: TiGenix (1) Acquired (1)

cx501 (1 trial)

stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Crohn Disease (Phase 3)

Fistula (Phase 3)

Fractures, Stress (Phase 3)

Pneumonia (Phase 2)

Pneumonia, Bacterial (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 6